Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors (2nd Edition)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: 20 November 2025 | Viewed by 1286
Special Issue Editor
Interests: clinical cancer research; biomarkers; genitourinary cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue is the second edition of a previous Special Issue entitled “Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors” (https://www.mdpi.com/journal/cancers/special_issues/QWO8SW601P).
Immunotherapy has revolutionized the treatment of cancer in recent years. Specifically, immune checkpoint inhibitors targeted to PD-1 or its ligand PD-L1 have changed the evolution of aggressive solid tumors, such as advanced lung cancer or melanoma. However, despite promising results, current immunotherapy is not effective for all patients, and, therefore, there is an urgent need for biomarker selection. PD-L1 measured by immunohistochemistry has demonstrated a correlation between expression and survival in some clinical trials, but these results have not been validated for all types of tumors and may vary depending on the antibody used in the different studies. Other tissue biomarkers, such as tumor mutational burden (TMB) or DNA repair defects (DRDs), have been explored, yielding controversial results. Some studies have reported that these alterations may release a higher number of tumor neoantigens, thus leading to an increased activation of the immune system and a greater benefit in terms of immunotherapy response. Another type of approach is to identify patient-dependent predictors of immunotherapy efficacy, such as the development of immune-related side effects or the identification of changes in immune phenotype. It may be particularly interesting to detect biomarkers in real time at different points of disease evolution to examine the constant dynamic changes of the immune system. This Special Issue will highlight the current complex uses of biomarkers in clinical practice and identify new potential immune biomarkers in solid tumors.
Dr. Nuria Romero-Laorden
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunotherapy
- checkpoint inhibitors
- biomarkers
- immune biomarkers
- PD-L1
- TMB
- solid tumors
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
